Publications by authors named "Mary Slavcev"

Claim this Profile
E
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].
Niodita Gupta-Werner, Joseph Goble, Mary Slavcev

Clinicoecon Outcomes Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Philippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, Hermann Einsele, Valerio De Stefano, Mary Slavcev

Adv Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Mary Slavcev

J Comp Eff Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Mary Slavcev

Adv Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
María-Victoria Mateos, Ajai Chari, Saad Z Usmani, Hartmut Goldschmidt, Katja Weisel, Mary Slavcev

Clin Lymphoma Myeloma Leuk· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Mary Slavcev, Allison Spinelli, Elisabeth Absalon, Tara Masterson, Christoph Heuck

Clinicoecon Outcomes Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Saad Z Usmani, Maria-Victoria Mateos, Vania Hungria, Shinsuke Iida, Nizar J Bahlis, Mary Slavcev

J Cancer Res Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Rafael Fonseca, Saad Z Usmani, Maneesha Mehra, Mary Slavcev, Jianming He

BMC Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, Thierry Facon, Bart Heeg, Mary Slavcev

Leuk Lymphoma· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.
Katja Weisel, Pieter Sonneveld, Andrew Spencer, Meral Beksac, Maria Rizzo, Mary Slavcev

Leuk Lymphoma· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
Meletios Athanasios Dimopoulos, Jonathan L Kaufman, Darrell White, Gordon Cook, Maria Rizzo, Mary Slavcev

Clin Lymphoma Myeloma Leuk· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis